One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
US Clean Air in the firing line
doi : 10.1016/S1470-2045(25)00294-3
Volume 26, Issue 6, June 2025, Page 663
Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions
Immunotherapy plus tyrosine-kinase inhibitors in hepatocellular carcinoma
Risk-reducing surgery in BRCA carriers: do we need more evidence?
Navigating the complexity: reflections on the development of perioperative cancer treatments
Promoting sustainability in oncology care: an international call to legalise the redispensing of unused oral anticancer drugs with quality assurance protocols
Young-PEARL trial: paradoxical results of overall survival – Authors' reply
Proposed tariffs on pharmaceuticals cause concerns about increased drug prices and drug shortages in the USA
New chemotherapy database to monitor ovarian cancer treatment in New Zealand
UK cancer researchers reaping the rewards of return to EU Horizon programme funding
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma
The BREAKING-ICE App: an interactive journey into informative censoring
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study
Nutrition in head and neck cancer care: a roadmap and call for research
Impact of suboptimal cancer care in the Commonwealth: a scoping review and call to action
National cancer control plans in Latin America and the Caribbean: challenges and future directions
